A Periodic Safety Update Report (PSUR) is a periodic safety report that summarises the current state of knowledge on the safety of a medicinal product. It assesses the benefit-risk balance over a defined reporting period and integrates new signals, cumulative case numbers and risk-minimisation measures. In the EU, the PSUR is a central pharmacovigilance instrument for authorised medicinal products.
Purpose and content of a PSUR
The PSUR serves to systematically document the continuous monitoring of medicinal product safety and to make it transparent to authorities. The focus is not only on individual serious adverse events, but on the overall picture of the safety data in relation to the therapeutic benefit.
- Summary of new data: clinical trials, non-interventional studies, literature, spontaneous reports, real-world evidence
- Signal detection: new safety signals, trends, identified risks and potential risks
- Benefit-risk assessment: updated assessment including subgroups, off-label context and interactions
- Measures: proposed changes to the Summary of Product Characteristics/package leaflet, additional risk minimisation, studies or PASS
It is important to clearly separate individual case handling (e.g. SUSAR reports in the clinical trial context) from the aggregated assessment in the post-authorisation lifecycle. The PSUR is therefore complementary to a Risk Management Plan, which structures the planned pharmacovigilance activities and risk minimisation.
A PSUR is also not merely a database extract. A traceable medical argument is expected: which events are expected? Which are new or conspicuous in their frequency? What clinical relevance do they have in different patient groups? This classification is particularly important when case numbers are small but the potential for harm is high.
EU regulatory framework and submission practice
In the EU, the PSUR obligation is based on pharmacovigilance legislation and the requirements of the Good Pharmacovigilance Practices (GVP). Submissions are typically made via central platforms and, depending on the product and authorisation route, can be evaluated through the PSUR Single Assessment (PSUSA). For many active substances, submission deadlines and data lock points are harmonised in the EURD list (EU Reference Dates).
For companies, this means that PSUR planning is not just a writing task, but an organisational process with fixed timelines, data interfaces (safety database, medical information, literature research) and internal approvals. In Germany, depending on the product context, national authority perspectives are also relevant, for example when risk communication via “Rote-Hand-Briefe” (Direct Healthcare Professional Communications) is discussed.
Standardised calendars (data lock point, data extraction, medical review, quality control, QPPV review, final dispatch) and clear responsibilities have proven effective in practice. Common bottlenecks arise at system boundaries: inconsistent MedDRA coding, delayed literature screenings or missing documentation of follow-up information. These points can be addressed via SOPs, training and a structured CAPA logic.
Differentiation from related safety documents
The PSUR is often confused with other safety and development reports. A clear distinction helps to avoid duplication of work and to meet regulatory expectations:
- DSUR (Development Safety Update Report): annual safety report for clinical trials in development, not for the routine post-marketing area.
- RMP (Risk Management Plan): describes risks and planned activities/measures; the PSUR provides the periodic evidence base for updates.
- PASS (Post-Authorisation Safety Study): specific study for risk clarification; can be derived from PSUR signals.
- PBRER: international term (Periodic Benefit-Risk Evaluation Report) with similar objectives; in the EU, the PSUR is often implemented in the sense of a PBRER.
In the clinical trial context, safety reports such as SUSARs and the ongoing reporting of serious adverse events to the sponsor and ethics committee are also relevant; however, these are time-critical individual reports and do not replace an aggregated PSUR.
Relevance for clinical trials
Although PSURs are primarily anchored in post-marketing, they indirectly influence clinical trials. Safety signals from the market can trigger protocol amendments, additional safety monitoring measures, adjustments to the investigator’s brochure or changes to inclusion/exclusion criteria. Especially for products in transition from Phase III programmes to commercial operation, safety and clinical teams must work closely together.
From a CRO and sponsor perspective, the PSUR is also an important component for integrated safety management: data flows, consistent MedDRA coding, traceable narratives and an audit trail must be correct across systems and teams. Full-service CROs like mediconomics support the integration of PSUR processes with medical writing, pharmacovigilance and quality management so that timelines are met and findings from audits or inspections are addressed.
Typical interfaces also include studies that continue after authorisation (e.g. long-term extension studies) or post-authorisation safety studies. Here, it must be transparent which data flows into the PSUR and how it is interpreted for the authorities, without mixing development and post-marketing processes.
Frequently Asked Questions (FAQ)
When is a PSUR required in the EU?
The obligation depends on the active substance and the regulatory requirements, in particular harmonised reference dates (EURD list) and authorisation conditions. For some products, the obligation may be suspended or the frequency adjusted if the benefit-risk profile is considered stable.
What is the difference between a PSUR and a DSUR?
The DSUR reports annually on the safety of an investigational medicinal product during clinical development. The PSUR periodically assesses the safety and benefit-risk balance of an authorised medicinal product in routine use.
What typical errors lead to queries from the authorities?
Common issues include data inconsistencies between the safety database and the report, unclear signal discussion, lack of contextualisation of case numbers or insufficiently justified benefit-risk conclusions. Delayed submissions or unresolved data lock points also cause delays.
Regulatory References
- EU Regulation (EC) No 726/2004 and Directive 2001/83/EC: Basic framework for the authorisation and pharmacovigilance of medicinal products for human use in the EU.
- GVP Module VII (Periodic safety update report): Guideline on the structure, submission and assessment of PSURs.
- ICH E2C(R2): International standard for Periodic Benefit-Risk Evaluation Reports (PBRER), on which many PSUR requirements are based.
Not to be confused with the Periodic Safety Update Report for medical devices according to Article 86 MDR: The PSUR according to this entry is handled via the EMA and national authorities under pharmaceutical law. The MDR PSUR only concerns medical devices of classes IIa to III and is part of the post-market surveillance documentation.